- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT05283525
Efficacy Of Trimrox On Body Recomposition And Weight Management (TRCAP21) (VNI)
Efficacy Of Trimrox On Body Composition, Body Weight, And Anthropometric Parameters In 100 Healthy Male And Female Volunteers
Protocol Number: VNI/121/TrimRox:
A unique stimulant- and sugar-free TRCAP21 Prodosomed® nutraceutical formulation, TrimROXTM, has been developed in a cGMP and NSF-certified manufacturing facility that is CFR-111 A compliant as well as having a BRC A rating, ensuring compliance with the Global Food Safety Initiative (GFSI). The investigators developed a stimulant- and sugar-free TRCAP21 Prodosomed® nutraceutical technology that effectively addresses directly and indirectly all the contributing factors. The investigators will conduct a 90-day study investigation in 100 study participants to assess the efficacy of TRCAP21 on diverse anthropometric aspects including chest, upper arms, waist/belly, hips and thighs, body weight, height, body mass index (BMI), and overall health and well-being.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
- Suplemento dietético: Anthropometric Measurement of the Chest, Upper Arm/Bicep, Hips, Thighs and Waist/ Belly in Inches
- Suplemento dietético: Oxygen Saturation
- Suplemento dietético: Total Blood Chemistry
- Suplemento dietético: Adverse Event Monitoring
- Suplemento dietético: Body Weight Monitoring
- Suplemento dietético: Physical well-being including mood, energy, satiety level. sugar cravings, sleep, and overall health
Descrição detalhada
CDC reports that in the USA, the prevalence of obesity was 40% in adults between 20 and 39 years, 44.8% in adults between 40 and 59 years, and 42.8% in people 60 years and older. Furthermore, the CDC emphasized that 49.6% of non-Hispanic Black adults exhibited the highest age-adjusted prevalence of obesity, which is followed by the occurrence of 44.8% in Hispanic adults, 42.2% in non-Hispanic White adults, and 17.4% in non-Hispanic Asian adults. Obesity-related conditions include diverse cardiovascular diseases and dysfunctions, stroke, Type 2 Diabetes, and certain types of cancer that are some of the leading causes of preventable, premature death. The estimated annual medical cost of obesity in the United States was $147 billion in 2008 US dollars; the medical cost for people who have obesity was $1,429 higher than those of normal weight. Overall, the obesity epidemic is increasing at an alarming rate worldwide. Because of the alarming rise in the global obesity epidemic, the terminologies "weight loss" and "weight management" have become common descriptors, even in the medical and scientific communities. However, the correct scientific terminology should more accurately refer to express changes in body composition and size, especially in regard to a reduction in fat mass, rather than weight reduction alone. In fact, the investigators will demonstrate that focusing on "weight" as an appropriate measuring criterion constitutes a contradiction and a misconception to the natural sequence of metabolic events in the body recomposition process. Overall, the term 'weight loss' is an unreliable metric as it automatically places the primary focus on the heaviness of the body and does not provide a correct and accurate perspective for evaluating healthy changes in metabolism, body composition, or size. For example, losing a small amount of fat while increasing muscle density, strength, and performance could result in a small increase in weight, as muscle is heavier than fat. It is especially important to highlight that fat is the lightest of pertinent macro molecules in the human body, lighter than water, muscle mass, and bone. Moreover, fat is usually 'the last to go' in the body recomposition process, therefore, creating short-term expectations in weight loss is erroneous and maybe even fraudulent.
A more comprehensive and accurate approach therefore is to fundamentally restore healthy efficient aerobic metabolism, improving oxygen utilization and management that enables competent cellular waste removal. Adversarial factors to that objective involve nutrient deprivation (the most common factor employed by weight loss products and programs), the imposition of various types of stimulants inducing, via feedback, regulatory energy-conserving retaliation in the form of even greater survival insurance storage; triggering the "yo-yo" rebound weight regain. Moreover, conventional weight loss tactics seem to ignore the biological, genetic, and metabolic consequences that occur with aging. Diminishing hormonal potencies are crucially important considerations that need to be addressed in the obesity epidemic. Cellular oxygen deprivation-induced anaerobic pathologies exacerbate and amplify the effects of diminished hormone functionality and contribute to an increasingly sluggish metabolism with increased fat, glycogen, and water storage. This also increases the detrimental strain on the cardiovascular system, kidneys, GI tract, and microbiome to name a few. The objective is to restore optimal systemic aerobic metabolism using a novel TRCAP21 nutraceutical formulation that addresses multiple biological pathways in order to reduce survival panic, restore survival safety, and correct metabolic homeostasis.
Tipo de estudo
Inscrição (Antecipado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: DR DEBASIS BAGCHI, PhD
- Número de telefone: 19259486951
- E-mail: debasisbagchi@gmail.com
Locais de estudo
-
-
Pennsylvania
-
Huntingdon Valley, Pennsylvania, Estados Unidos, 19006
- Recrutamento
- Dr Bruce S. Morrison
-
Contato:
- Bruce S Morrison, DO
- Número de telefone: 215-947-9131
- E-mail: drmorrisonfm@gmail.com
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria
- Agrees to sign written and audio-visual informed consent.
- Fully understand the risks and benefits of the study
- Male and Female Subjects (age: 30-70 Y)
- Subjects are deemed to be acceptable for this study by their physician
Exclusion Criteria
- Subjects who are unwilling or uncooperative subjects
- Subjects were excluded who had impaired hepatic functions i,e., SGOT/SGPT >2.5 X
- Subjects suffering from type 1 diabetes
- Subjects suffering from type 2 diabetes or anyone else that has a blood glucose levels >180 mg/dl or HbA1c > 8.
- Subjects who were suffering from coronary artery disease or high blood pressure >180/100
- Subjects who were exhibiting abnormal hepatic or kidney functions (ALT or AST > 2 X greater than normal value); elevated creatinine, males > 125 μmol/L or 1.4mg/dl
- Subjects who have cancer and are suffering from a malignancy.
- Hypersensitivity to the investigational supplement
- Subjects who had used any known weight management supplement for the last 2 months.
- History of blood coagulation and bleeding (coagulopathies)
- Incidence of high alcohol intake (more than 2 standard drinks/day).
- Psychiatric disorder/disability provide signed informed consent.
Existing medical condition of the participant, which may be detrimental to the study and subject's overall well-being.
__________________________________________________________________
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Cuidados de suporte
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Comparador de Placebo: Placebo Group #1 (6.75 gms Once-A-Day)
Placebo Group #1 (1 Dose; 6.75 gms per day): A total of 25 subjects will be given 1 placebo sachet; To be taken one in the morning in an empty stomach over a period of 90 consecutive days
|
0 - 90 Days of Treatment
Outros nomes:
0 - 90 Days of Treatment
0 and 90 Days of Treatment
Adverse Event Monitoring Throughout the Study
0 - 90 Days of Treatment
Outros nomes:
0 - 90 Days of Treatment
Outros nomes:
|
Comparador de Placebo: Placebo Group #2 (6.75 gms Twice-A-Day)
Placebo Group #2 (2 Doses; 13.5 gms in two divided doses per day): A total of 25 subjects will be given 2 placebo sachets; To be taken one in the morning in an empty stomach and the other in the afternoon in an empty stomach over a period of 90 consecutive days
|
0 - 90 Days of Treatment
Outros nomes:
0 - 90 Days of Treatment
0 and 90 Days of Treatment
Adverse Event Monitoring Throughout the Study
0 - 90 Days of Treatment
Outros nomes:
0 - 90 Days of Treatment
Outros nomes:
|
Comparador Ativo: TRCAP21 Group #1 (6.75 gms Once-A-Day)
TRCAP21 Group #1 (1 Dose; 6.75 gms per day): A total of 25 subjects will be given 1 TRCAP21 sachet; To be taken one in the morning in an empty stomach over a period of 90 consecutive days
|
0 - 90 Days of Treatment
Outros nomes:
0 - 90 Days of Treatment
0 and 90 Days of Treatment
Adverse Event Monitoring Throughout the Study
0 - 90 Days of Treatment
Outros nomes:
0 - 90 Days of Treatment
Outros nomes:
|
Comparador Ativo: TRCAP21 Group #2 (6.75 gms Twice-A-Day)
TRCAP21 Group #2 (2 Doses; 13.5 gms in two divided doses per day): A total of 25 subjects will be given 2 TRCAP21 sachets; To be taken one in the morning in empty stomach and the other in the afternoon in an empty stomach over a period of 90 consecutive days
|
0 - 90 Days of Treatment
Outros nomes:
0 - 90 Days of Treatment
0 and 90 Days of Treatment
Adverse Event Monitoring Throughout the Study
0 - 90 Days of Treatment
Outros nomes:
0 - 90 Days of Treatment
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Anthropometric Measurement of the Chest (in Inches)
Prazo: 0 Day of Treatment
|
Anthropometric Measurement of the Chest (in Inches)
|
0 Day of Treatment
|
Anthropometric Measurement of the Chest (in Inches)
Prazo: 30 Day of Treatment
|
Anthropometric Measurement of the Chest (in Inches)
|
30 Day of Treatment
|
Anthropometric Measurement of the Chest (in Inches)
Prazo: 60 Day of Treatment
|
Anthropometric Measurement of the Chest (in Inches)
|
60 Day of Treatment
|
Anthropometric Measurement of the Chest (in Inches)
Prazo: 90 Days of Treatment
|
Anthropometric Measurement of the Chest (in Inches)
|
90 Days of Treatment
|
Anthropometric Measurement of the Upper Arm/Bicep (in Inches)
Prazo: 0 Day of Treatment
|
Anthropometric Measurement of the Upper Arm/Bicep (in Inches)
|
0 Day of Treatment
|
Anthropometric Measurement of the Upper Arm/Bicep (in Inches)
Prazo: 30 Days of Treatment
|
Anthropometric Measurement of the Upper Arm/Bicep (in Inches)
|
30 Days of Treatment
|
Anthropometric Measurement of the Upper Arm/Bicep (in Inches)
Prazo: 60 Days of Treatment
|
Anthropometric Measurement of the Upper Arm/Bicep (in Inches)
|
60 Days of Treatment
|
Anthropometric Measurement of the Upper Arm/Bicep (in Inches)
Prazo: 90 Days of Treatment
|
Anthropometric Measurement of the Upper Arm/Bicep (in Inches)
|
90 Days of Treatment
|
Anthropometric Measurement of the Hip (in Inches)
Prazo: 0 Day of Treatment
|
Anthropometric Measurements of the Hip (in Inches)
|
0 Day of Treatment
|
Anthropometric Measurement of the Hip (in Inches)
Prazo: 30 Days of Treatment
|
Anthropometric Measurements of the Hip (in Inches)
|
30 Days of Treatment
|
Anthropometric Measurement of the Hip (in Inches)
Prazo: 60 Days of Treatment
|
Anthropometric Measurements of the Hip (in Inches)
|
60 Days of Treatment
|
Anthropometric Measurement of the Hip (in Inches)
Prazo: 90 Days of Treatment
|
Anthropometric Measurements of the Hip (in Inches)
|
90 Days of Treatment
|
Anthropometric Measurement of the Thighs (in Inches)
Prazo: 0 Day of Treatment
|
Anthropometric Measurement of the Thighs (in Inches)
|
0 Day of Treatment
|
Anthropometric Measurement of the Thighs (in Inches)
Prazo: 30 Days of Treatment
|
Anthropometric Measurement of the Thighs (in Inches)
|
30 Days of Treatment
|
Anthropometric Measurement of the Thighs (in Inches)
Prazo: 60 Days of Treatment
|
Anthropometric Measurement of the Thighs (in Inches)
|
60 Days of Treatment
|
Anthropometric Measurement of the Thighs (in Inches)
Prazo: 90 Days of Treatment
|
Anthropometric Measurement of the Thighs (in Inches)
|
90 Days of Treatment
|
Anthropometric Measurement of the Waist/Belly (in Inches)
Prazo: 0 Day of Treatment
|
Anthropometric Measurements of the Waist/Belly (in Inches)
|
0 Day of Treatment
|
Anthropometric Measurement of the Waist/Belly (in Inches)
Prazo: 30 Days of Treatment
|
Anthropometric Measurements of the Waist/Belly (in Inches)
|
30 Days of Treatment
|
Anthropometric Measurement of the Waist/Belly (in Inches)
Prazo: 60 Days of Treatment
|
Anthropometric Measurements of the Waist/Belly (in Inches)
|
60 Days of Treatment
|
Anthropometric Measurement of the Waist/Belly (in Inches)
Prazo: 90 Days of Treatment
|
Anthropometric Measurements of the Waist/Belly (in Inches)
|
90 Days of Treatment
|
Body Weight Measurement (in Kilograms)
Prazo: 0 Day of Treatment
|
Body Weight Measurements (in Kilograms)
|
0 Day of Treatment
|
Body Weight Measurement (in Kilograms)
Prazo: 30 Days of Treatment
|
Body Weight Measurements (in Kilograms)
|
30 Days of Treatment
|
Body Weight Measurement (in Kilograms)
Prazo: 60 Days of Treatment
|
Body Weight Measurements (in Kilograms)
|
60 Days of Treatment
|
Body Weight Measurement (in Kilograms)
Prazo: 90 Days of Treatment
|
Body Weight Measurements (in Kilograms)
|
90 Days of Treatment
|
Height Measurement (in Centimeters)
Prazo: 0 Day of Treatment
|
Height Measurement (in Centimeters)
|
0 Day of Treatment
|
Height Measurement (in Centimeters)
Prazo: 30 Days of Treatment
|
Height Measurement (in Centimeters)
|
30 Days of Treatment
|
Height Measurement (in Centimeters)
Prazo: 60 Days of Treatment
|
Height Measurement (in Centimeters)
|
60 Days of Treatment
|
Height Measurement (in Centimeters)
Prazo: 90 Days of Treatment
|
Height Measurement (in Centimeters)
|
90 Days of Treatment
|
BMI (body mass index) Measurement (in kg/m^2)
Prazo: 0 Day of Treatment
|
BMI (body mass index)(kg/m^2)
|
0 Day of Treatment
|
BMI (body mass index) Measurement (in kg/m^2)
Prazo: 30 Days of Treatment
|
BMI (body mass index)(kg/m^2)
|
30 Days of Treatment
|
BMI (body mass index) Measurement (in kg/m^2)
Prazo: 60 Days of Treatment
|
BMI (body mass index)(kg/m^2)
|
60 Days of Treatment
|
BMI (body mass index) Measurement (in kg/m^2)
Prazo: 90 Days of Treatment
|
BMI (body mass index)(kg/m^2)
|
90 Days of Treatment
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Systolic and Diastolic Blood Pressure Measurements (in mmHg)
Prazo: 0 Day of Treatment
|
Systolic and Diastolic Blood Pressure Measurements (mmHg)
|
0 Day of Treatment
|
Systolic and Diastolic Blood Pressure Measurements (in mmHg)
Prazo: 30 Days of Treatment
|
Systolic and Diastolic Blood Pressure Measurements (mmHg)
|
30 Days of Treatment
|
Systolic and Diastolic Blood Pressure Measurements (in mmHg)
Prazo: 60 Days of Treatment
|
Systolic and Diastolic Blood Pressure Measurements (mmHg)
|
60 Days of Treatment
|
Systolic and Diastolic Blood Pressure Measurements (in mmHg)
Prazo: 90 Days of Treatment
|
Systolic and Diastolic Blood Pressure Measurements (mmHg)
|
90 Days of Treatment
|
Pulse Rate Measurement (in beats per minute; bpm)
Prazo: 0 Day of Treatment
|
Pulse Rate (beats per minute; bpm)
|
0 Day of Treatment
|
Pulse Rate Measurement (in beats per minute; bpm)
Prazo: 30 Days of Treatment
|
Pulse Rate (beats per minute; bpm)
|
30 Days of Treatment
|
Pulse Rate Measurement (in beats per minute; bpm)
Prazo: 60 Days of Treatment
|
Pulse Rate (beats per minute; bpm)
|
60 Days of Treatment
|
Pulse Rate Measurement (in beats per minute; bpm)
Prazo: 90 Days of Treatment
|
Pulse Rate (beats per minute; bpm)
|
90 Days of Treatment
|
Saturation of Oxygen in Red Blood Cells (Pulse Ox Measurements; SpO2%)
Prazo: 0 Day of Treatment
|
Pulse Ox Measurement (SpO2%)
|
0 Day of Treatment
|
Saturation of Oxygen in Red Blood Cells (Pulse Ox Measurements; SpO2%)
Prazo: 30 Days of Treatment
|
Pulse Ox Measurement (SpO2%)
|
30 Days of Treatment
|
Saturation of Oxygen in Red Blood Cells (Pulse Ox Measurements; SpO2%)
Prazo: 60 Days of Treatment
|
Pulse Ox Measurement (SpO2%)
|
60 Days of Treatment
|
Saturation of Oxygen in Red Blood Cells (Pulse Ox Measurements; SpO2%)
Prazo: 90 Days of Treatment
|
Pulse Ox Measurement (SpO2%)
|
90 Days of Treatment
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Antecipado)
Conclusão do estudo (Antecipado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- VNI-TRIMROX-2022
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Prazo de Compartilhamento de IPD
Critérios de acesso de compartilhamento IPD
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
- CIF
- ANALYTIC_CODE
- CSR
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Alterações de Peso Corporal
-
University of MichiganNational Institute on Aging (NIA)ConcluídoLewy Body Dementia Com Distúrbio Comportamental | Doença de corpos de Lewy | Variante do corpo de Lewy da doença de AlzheimerEstados Unidos
-
University Hospital, Strasbourg, FranceDesconhecidoDoença de Alzheimer | Demência de Lewy BodyFrança
-
University of PennsylvaniaNational Institute on Aging (NIA)RecrutamentoDoença de Parkinson | Lewy Body Dementia Com Distúrbio Comportamental | Doença de Parkinson com corpos de Lewy | Doença de Parkinson DemênciaEstados Unidos
-
University of FloridaNational Institute on Aging (NIA)RecrutamentoLewy Body Dementia Com Distúrbio Comportamental | Doença de Parkinson com corpos de Lewy | Doença de corpos de LewyEstados Unidos
-
University of FloridaNational Institute on Aging (NIA); Aster Labs, IncConcluídoLewy Body Dementia Com Distúrbio Comportamental | Demência Vascular | Demência de AlzheimerEstados Unidos
-
Rutgers UniversityDesconhecidoDoença de Alzheimer | Parkinson | Demência, tipo Alzheimer | Demência com corpos de Lewy | Síndrome de Asperger | Espectro de transtornos autistas | TDAH | Lewy Body Dementia Com Distúrbio Comportamental (Transtorno) | Demência Frontal | Tremor EssencialEstados Unidos
-
University of RochesterUniversity of Colorado, Denver; Massachusetts General Hospital; Stanford UniversityRecrutamentoDoença de Parkinson | Atrofia de Múltiplos Sistemas | Degeneração corticobasal | Paralisia Supranuclear Progressiva | Doença de Parkinson e Parkinsonismo | Demência com corpos de Lewy | Parkinsonismo vascular | Doença de Parkinson Demência | Lewy Body parkinsonismoEstados Unidos
-
MD Stem CellsInscrevendo-se por conviteDoença de Alzheimer | Traumatismo crâniano | Transtorno do Espectro Autista | Doença de corpos de Lewy | Demencia vascular | Autismo | Demência, Mista | Demência de Alzheimer | Demência, Infarto Múltiplo | Cadasil | Parkinson-Síndrome Demencial | Encefalopatia Traumática Crônica | Comportamento Autista | Lewy Body Dementia... e outras condiçõesEstados Unidos, Emirados Árabes Unidos